David Risinger

Pfizer, Moderna Analysts Respond To FDA COVID Booster Ruling: 'Revenues Will Decline'
Pfizer Analysts Raise Odds Of Success For Coronavirus Vaccine Candidate To 100%
Why Morgan Stanley Is Buying The Dip In Eli Lilly
Pfizer Analysts Raise Odds Of Success For Coronavirus Vaccine Candidate To 100%
Why Morgan Stanley Is Buying The Dip In Eli Lilly
AbbVie's Potential Is 'Underappreciated," Says Morgan Stanley Analyst
BofA Downgrades Lilly On Valuation, Says Growth, Pipeline Potential Balanced By Stock Premium

David Risinger Recent News

Large Option Trader Makes Aggressive Bearish Play On Teva
|
Morgan Stanley Downgrades Teva, Endo On Drug Pricing And Litigation Concerns
|
Morgan Stanley Loses Confidence In Allergan's Pipeline Optionality
|
Morgan Stanley Turns Bullish On Bausch Health: 'We Expect 2018 To Be The Last Year Of Declining Financials'
|
Teva To Deliver Cost Cuts, Earnings Surprise In Coming Years, Morgan Stanley Says In Upgrade
|
3 Headwinds Hindering Mylan
|
Morgan Stanley Downgrades Jazz Pharmaceuticals As Stock Approaches Price Target
|
One Up, One Down: Morgan Stanley Flips Merck, Bristol-Myers Ratings
|
Zoetis Downgraded As Valuation Approaches Morgan Stanley's Price Target
|
Morgan Stanley: As Generic Competitors Falter, Mylan Is Worth A Shot
|
Morgan Stanley Targets New All-Time High For Bristol-Myers, Upgrades To Overweight
|
Analyst: Zoetis Deserves To Trade At A Premium
|
The Bull Thesis For Merck Is Evaporating
|
Pfizer Should Outperform, Morgan Stanley Upgrades
|
Mylan Price Target Slashed Even As TLD Drug Receives Tentative Approval
|
Merck's Leadership Position In Immuno Oncology Is Improving
|
Morgan Stanley Cuts Teva's Price Target By 33%
|
Morgan Stanley Cuts Valeant's Target To $25, Admits It Got A Couple Things Wrong
|

Connect With Us

instagramlinkedinyoutube

About Benzinga

Market Resources

Trading Tools & Education

Ring the Bell

© 2025 Benzinga | All Rights Reserved